Stock OCS OCULIS HOLDING AG
Add to a list
To use this feature you must be a member
Log inSign up

News Oculis Holding AG

Equities

OCS

CH1242303498

End-of-day quote Nasdaq
Other stock markets
 06:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
11.01 USD -4.26% Intraday chart for Oculis Holding AG -6.10% -1.96%
Jun. 11 BofA Securities Adjusts Oculis Holding AG to $20 From $21, Maintains Buy Rating MT
Jun. 11 Baird Adjusts Price Target on Oculis Holding to $37 From $35, Maintains Outperform Rating MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
OCULIS AND EURETINA ANNOUNCES THE RAMIN TADAYONI AWARD
AQ
Oculis and EURETINA Announces the Ramin Tadayoni Award
AQ
BofA Securities Adjusts Oculis Holding AG to $20 From $21, Maintains Buy Rating
MT
Baird Adjusts Price Target on Oculis Holding to $37 From $35, Maintains Outperform Rating
MT
HC Wainwright Adjusts Price Target on Oculis Holding to $30 From $28, Maintains Buy Rating
MT
Oculis Sees Favorable Topline Results in Study of Potential Dye-Eye Disease Treatment
MT
Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
GL
Oculis Holding AG Announces Positive Topline Results of Phase 2b RelieF Trial with Licaminlimab Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy
CI
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
GL
Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board
GL
Oculis Holding AG Announces Board and Committee Appointments
CI
Oculis Holding AG announced a financing transaction
CI
Oculis Holding - Increase in share capital
AQ
Oculis updates share capital for its existing at-the-market offering program
GL
Oculis : Entry into Sales Agreement with Leerink Partners, LLC - Form 6-K
PU
Oculis : Form 6-K
PU
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
GL
Oculis Holding AG Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis
AQ
Oculis Publishes Invitation to the Annual General Meeting
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCS Stock
  4. News Oculis Holding AG